FOLH1 and prostate cancer: To complement these innovations, antibody fragments were labelled with the stable isotope, 89Y, allowing ICP-MS quantification of 89Y excretion in urine.22 More recently, the radiotracers 177Lu-PSMA-617 and 161Tb-PSMA-617 have demonstrated efficacy in systemic radiotherapy of prostate cancer.